@article{3219587,
    title = "Article Conformational Properties of New Thiosemicarbazone and Thiocarbohydrazone Derivatives and Their Possible Targets",
    author = "Georgiou, N. and Katsogiannou, A. and Skourtis, D. and Iatrou, H. and Tzeli, D. and Vassiliou, S. and Javornik, U. and Plavec, J. and Mavromoustakos, T.",
    journal = "Molecules (Basel, Switzerland)",
    year = "2022",
    volume = "27",
    number = "8",
    publisher = "MDPI",
    doi = "10.3390/molecules27082537",
    keywords = "cholinesterase;  thiosemicarbazone derivative, conformation;  nuclear magnetic resonance;  nuclear magnetic resonance spectroscopy;  procedures, Butyrylcholinesterase;  Magnetic Resonance Spectroscopy;  Molecular Conformation;  Nuclear Magnetic Resonance, Biomolecular;  Thiosemicarbazones",
    abstract = "The structure assignment and conformational analysis of thiosemicarbazone KKI15 and thiocarbohydrazone KKI18 were performed through homonuclear and heteronuclear 2D Nuclear Magnetic Resonance (NMR) spectroscopy (2D-COSY, 2D-NOESY, 2D-HSQC, and 2D-HMBC) and quantum mechanics (QM) calculations using Functional Density Theory (DFT). After the structure identification of the compounds, various conformations of the two compounds were calculated using DFT. The two molecules showed the most energy-favorable values when their two double bonds adopted the E configuration. These configurations were compatible with the spatial correlations observed in the 2D-NOESY spectrum. In addition, due to the various isomers that occurred, the energy of the transition states from one isomer to another was calculated. Finally, molecular binding experiments were performed to detect potential targets for KKI15 and KKI18 derived from Swis-sAdme. In silico molecular binding experiments showed favorable binding energy values for all four enzymes studied. The strongest binding energy was observed in the enzyme butyrylcholinesterase. ADMET calculations using the preADMET and pKCSm software showed that the two molecules appear as possible drug leads. © 2022 by the authors. Licensee MDPI, Basel, Switzerland."
}